T. Rowe Price Associates’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
|
|||||
|
2025
Q2 | $2M | Buy |
|
|||||
|
2025
Q1 | $1.83M | Buy |
|
|||||
|
2024
Q4 | $1.66M | Buy |
|
|||||
|
2024
Q3 | $1.61M | Buy |
|
|||||
|
2024
Q2 | $1.51M | Sell |
|
|||||
|
2024
Q1 | $2.88M | Buy |
|
|||||
|
2023
Q4 | $2.94M | Sell |
|
|||||
|
2023
Q3 | $3.28M | Sell |
|
|||||
|
2023
Q2 | $20.9M | Sell |
|
|||||
|
2023
Q1 | $18.4M | Sell |
|
|||||
|
2022
Q4 | $22.8M | Sell |
|
|||||
|
2022
Q3 | $33.5M | Sell |
|
|||||
|
2022
Q2 | $78.4M | Sell |
|
|||||
|
2022
Q1 | $158M | Sell |
|
|||||
|
2021
Q4 | $201M | Sell |
|
|||||
|
2021
Q3 | $190M | Sell |
|
|||||
|
2021
Q2 | $363M | Sell |
|
|||||
|
2021
Q1 | $409M | Sell |
|
|||||
|
2020
Q4 | $458M | Buy |
|
|||||
|
2020
Q3 | $357M | Sell |
|
|||||
|
2020
Q2 | $302M | Sell |
|
|||||
|
2020
Q1 | $285M | Sell |
|
|||||
|
2019
Q4 | $263M | Buy |
|
|||||
|
2019
Q3 | $195M | Buy |
|
|||||
|
2019
Q2 | $164M | Buy |
|
|||||
|
2019
Q1 | $43.1M | Buy |
|
|||||
|
2018
Q4 | $34.5M | Buy |
|
|||||
|
2018
Q3 | $24.5M | Buy |
|
|||||
|
2018
Q2 | $997K | Buy |
|
|||||
|
2018
Q1 | $702K | Sell |
|
|||||
|
2017
Q4 | $731K | Sell |
|
|||||
|
2017
Q3 | $777K | Buy |
|
|||||
|
2017
Q2 | $778K | Hold |
|
|||||
|
2017
Q1 | $632K | Sell |
|
|||||
|
2016
Q4 | $656K | Buy |
|